Hematological Disorders in EHPVO Patients

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorRahab Nady

About this trial

This study focuses on patients who have a condition called extrahepatic portal vein obstruction (EHPVO), where a blood clot blocks the portal vein outside the liver. This blockage can cause problems like an enlarged spleen, bleeding from swollen veins in the digestive system, and low blood cell counts. Many of these patients may have hidden blood disorders that increase the risk of clotting, such as myeloproliferative neoplasms (MPNs), antiphospholipid syndrome (APS), or paroxysmal nocturnal hemoglobinuria (PNH). This study will collect and analyze blood test results-such as complete blood count (CBC), liver function tests (LFTs), and clotting tests-from patients with EHPVO. The aim is to find patterns that may suggest an underlying blood disorder, even if the patient doesn't show obvious symptoms.By understanding these patterns early, doctors may be able to diagnose and treat the root causes of clotting in these patients more accurately, helping prevent complications and improve outcomes.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18 years or older . Diagnosis of extra hepatic portal vein obstruction based on imaging ( Doppler, CT , MRI ) preserved liver function . Available complete medical records including CBC , LFTs and coagulation profile .

Disqualifiers

Patients with cirrhosis or intrahepatic portal hypertension • Incomplete or missing medical records • Patients with known hematologic malignancies or undergoing chemotherapy

Trial population

Adult patients diagnosed with EHPVO between 2020 and 2024 in a tertiary care hospital in Cairo. Data will be collected retrospectively from medical records

Trial design

Design model

Case-only

Time perspective

Retrospective

Treatments tested in this trial

  • No intervention (Observational Study)

    Other intervention

    This is a retrospective observational study with no assigned intervention. Data will be collected from patient medical records only

Treatment groups

115 Participants
are divided into 1 treatment group
Group A: EHPVO Patients1 intervention

Trial outcomes

Primary outcomes

1

Frequency of hematological disorders in EHPVO patients

The proportion of EHPVO Patients showing hematological disorders including cytopenias ( thrombocytopenia , anemia , leukopenia ) and coagulation disturbances based on retrospective laboratory data

Time frame
Over a retrospective period from 2020 to 2024
2

Frequency of hematological disorders in EHPVO patients

Time frame
Over a retrospective period from 2020 to 2024

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Rahab Nady

Lead sponsor

Assiut University

Sponsor institution

This trial is not recruiting at the moment. You can still explore other options: